Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014779
Filing Date
2025-04-21
Accepted
2025-04-21 17:23:02
Documents
21
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20044429x1_def14a.htm   iXBRL DEF 14A 569010
6 logo_gyre.jpg GRAPHIC 34472
7 ny20044429x1_pvp02.jpg GRAPHIC 209410
8 ny20044429x1_pc01.jpg GRAPHIC 620443
9 ny20044429x1_pc02.jpg GRAPHIC 700611
10 ny20044429x1_pvp01x1.jpg GRAPHIC 175871
  Complete submission text file 0001140361-25-014779.txt   5657238

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE gyre-20250604_def.xml EX-101.DEF 3077
3 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE gyre-20250604_pre.xml EX-101.PRE 7891
4 INLINE XBRL TAXONOMY EXTENSION - SCHEMA gyre-20250604.xsd EX-101.SCH 3397
5 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE gyre-20250604_lab.xml EX-101.LAB 3252
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20044429x1_def14a_htm.xml XML 149157
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51173 | Film No.: 25854452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)